Cambrex Corporation operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Cambrex with three other
companies in this sector in the United States:
Emergent BioSolutions, Inc.
sales of $488.78 million
Swedish Orphan Biovitrum AB (publ)
of which 41%
was Haemophilia: Elocta), and
of which 100%
was Product research reve).
Cambrex reported sales of $490.34 million
December of 2016.
increase of 13.0%
versus 2015, when the company's sales were $433.93 million.
Sales at Cambrex have increased during each of the previous five years
(and since 2011, sales have increased a total of 92%).